Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study Abstract #999

Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Aim(s): To evaluate in a prospective study P-CT changes in pNET liver metastasis (LM) during E.
Materials and methods: We evaluated eight LM from three patients with G1-2 pNETs. P-CT was performed at baseline (T0), after two (T1) and four (T2) months of E on a 64-row multidetector CT scan. A single ROI was drawn within each LM on the main axial slice. Perfusion (PF), Time to Peak (TTP), Peak Enhancement Intensity (PEI) and Blood Volume (BV) were calculated.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.
Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1705 Prostate-Specific Membrane Antigen (PSMA) Uptake in a Pancreatic Neuroendocrine Tumor (pNET) Bearing Patient
Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed on both prostate epithelial malignant cells and endothelial cells of tumor-associated neovasculature of many solid cancers. PSMA has been investigated already as a target in staging and detection of prostate cancer
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
#1007 Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study
Introduction: Everolimus (E) acts on cancer progression, even inhibiting tumor angiogenesis. Both tumor vasculature and a normal one could undergo everolimus effect.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus
Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, Everolimus, mTOR